A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This prospective, randomized, single-blind, cross-over study will compare the bioavailability
of Copegus (ribavirin) administered as tablets and ribavirin administered as capsules in
healthy volunteers. Volunteers will be randomized to receive a single dose of 400 mg of
ribavirin either as a capsule or as tablets; after a washout phase volunteers will be
crossed-over to the other treatment. The anticipated time on study treatment is 10 days.